

****Must Attach Demographic Face Sheet******PATIENT INFORMATION**

Patient Name: _____ DOB: _____
Address: _____ Address 2: _____
City: _____ State: _____ Zip Code: _____
Phone Number: _____ E-mail: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ NPI: _____
Address: _____ Address 2: _____
City: _____ State: _____ Zip Code: _____
Office Contact: _____ Email: _____
Phone Number: _____ Fax Number: _____

PRESCRIPTION INFORMATION

Rx: **Nerivio** Quantity: 1 Refills ☐ 12 ☐ Other _____

Diagnosis (Select ICD10): ☐ **G43.** ____ (Fill in 3 digits to complete diagnosis code)

Directions: Set a strong, yet comfortable intensity level for each 45 min treatment

- ☐ Acute: 45 min treatment at onset of migraine
☐ Prevention: 45 min treatment every other day, or as directed
☐ Dual Use: 45 min treatment every other day for prevention or at onset of migraine

Clinical Criteria - Check all that apply:

- ☐ Patient at risk of drug-drug interaction with other medications they consume
☐ Patient aged 12-17 years old
☐ Check all triptan medications that have been tried and failed
○ Eletriptan ○ Frovatriptan ○ Naratriptan ○ Rizatriptan ○ Zolmitriptan
○ Sumatriptan ○ Almotriptan ○ Sumatriptan/Naproxen ○ Other: _____

Prescriber Signature: _____ **Date:** _____

PATIENT SIGNATURE: With signature and a \$0 copay the first device will be shipped automatically

By signing below I certify and acknowledge: (i) this request is made voluntarily; (ii) the information I provide above is correct; (iii) ProCare Pharmacy Care ("ProCare") may contact me by email, phone call or text to convey information relating to the fulfillment of my prescription; (iv) if my commercial insurance covers NERIVIO and my out of pocket copay due after applying manufacturer's coupon is \$0, ProCare may ship only my first order without contacting me further (offer not valid for patients using Medicare Part D benefits); (v) I may need to contact ProCare to obtain subsequent refills; and (vi) ProCare may, at ProCare's sole discretion, transfer my prescription to an external partner pharmacy for fulfillment; (vii) I may cancel any and all authorizations provided here by contacting ProCare at any time at (877) 210-1206; and (viii) if not canceled all authorizations will expire five years from the date of this form.

Patient Signature: _____ **Date:** _____

METHODS OF PATIENT ENROLLMENT FOR NERIVIO:

Fax: 855-818-3781 | Phone: 877-210-1206 | Email: neriviorx@procarerx.com

E-prescribe to ProMod Rx (Miramar, FL)

NCPDP: 5742627 NPI: 1396394805

Nerivio
by theranica

Complete
Migraine Care

One Device for Effective Migraine Prevention and Treatment

Nerivio is a wearable migraine therapy that is safe and effective for preventing and treating migraine in patients ages 12 years and up.

Preventing Migraine¹

4
LESS

Monthly
Migraine
Days




Over half
of patients
had a

≥50%
reduction

in moderate
to severe
headache days.

Acute Treatment of Migraine²

Adults at 2-hours Post Treatment



Clinical trials demonstrate that Nerivio provides consistent relief of pain and associated migraine symptoms, as well as significant reduction in monthly migraine days

Effective • Drug Free • Discreet • Wearable

Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse.


Nerivio
by theranica

57% of Adult Chronic patients achieved relief 2-hours post treatment with Nerivio.^{3,4}

72% of adolescent patients ages 12 and up achieved pain relief 2-hours post treatment with Nerivio.⁵

Pivotal Acute Study in Adult Episodic Patients²


Prospective, randomized, double-blind, placebo controlled, multi-center study, (n=252)



After only one month, patients using Nerivio every other day showed a significant reduction in the number of migraine days per month.¹

Pivotal Prevention Study

Prospective, randomized, double-blind, placebo controlled, multi-center study, (n=248)



Significant reduction of MMD was reported in patients whether or not they were taking other preventive treatment in addition to Nerivio vs. placebo ($p \leq 0.03$).

Of the 128 Nerivio patients studied, zero patients reported device related adverse events in the pivotal prevention trial.¹

Scan here for clinical study info



1. Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023. doi: 10.1111/head.14469.
2. Yarnitsky D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. 2019;59(8): 1240-1252. doi: 10.1111/head.13551.
3. Nierenburg H, et al. (2020): Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study. doi.org/10.1007/s40122-020-00185-1.
4. Grosberg B, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep. 2021; 6(4). doi: 10.1097/PR9.0000000000000966.
5. Hershey AD, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. 2020;00:1-8. 59(8): 1240-1252. doi.org/10.1111/head.14042.

Scan here for important safety info

